At Home Campaign Raises $116,000 for Leukemia and Lymphoma Society

At Home Campaign Raises $116,000 for Leukemia and Lymphoma Society

A campaign promoted by At Home, a home décor store chain headquartered in Plano, Texas, raised $116,232 through customer donations during May for the Leukemia and Lymphoma Society (LLS).

More than 100 At Home stores participated in the campaign, which allowed people to contribute at check-out registers.

“Thanks to the generosity, and continued support from At Home, The Leukemia & Lymphoma Society is doing more than any health non-profit organization to advance cures and access for blood cancer patients and is having an impact beyond the blood cancers,” said LLS President and CEO Louis DeGennaro, in a press release. “We are saving lives not someday, but today.”

The $116,232 donation will fund promising, groundbreaking research projects focused on blood cancer worldwide. The money will also help ensure that patients have access to potentially life-saving treatments.

“As a company, one of our core values is to always do the right thing,” added Lee Bird, CEO of At Home. “We were thrilled to see our At Home team members across the nation come together with our customers to raise money and awareness for such a worthy cause.”

The Leukemia and Lymphoma Society was founded in 1949 and is now the world’s largest voluntary health organization dedicated to blood cancers. Headquartered in Rye Brook, New York, LLS boasts chapters throughout the United States and Canada. The recent campaign marked the second time for At Home to collaborate with LLS at a national level.

Read More Recent News

Epizyme announced new and positive data from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of orally administered tazemetostat in relapsed or refractory patients with non-Hodgkin’s lymphoma.

The findings were presented at the 2016 American Society of Hematology Meeting on Lymphoma Biology in the study “Initial report from a phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Leave a Comment

Your email address will not be published. Required fields are marked *